Company / Operating Cash Flow
AMICUS THERAPEUTICS, INC. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$33.1M
FY2025
5-year range
-$202.5M / $33.1M
FY2021-FY2025
Trend
+197.8%
vs FY2024
Sector context
#69 of 216
Health Care
What the data says
At $33M, AMICUS THERAPEUTICS, INC.'s operating cash flow ranks #69 of 216 in the Health Care sector. Operating Cash Flow has increased for 7 consecutive years, from -$300M in FY2018 to $33M in FY2025.
Based on SEC 10-K filings.
$33M in FY2025.
Improved from -$69M to $33M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#69 of 216 in Health CareTop 32% of 216This company $33.1M Sector average $658.7M
▼
-95.0% below sector average
Key checks
Key Insights
- AMICUS THERAPEUTICS, INC.'s operating cash flow has grown for 7 consecutive years.
- In FY2025, operating cash flow increased 197.8% year-over-year.
- Ranks #69 out of 216 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -1.19 (distress zone, below 1.8 threshold)
- Negative profit margin: -10.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $33.1M | +197.8% |
| FY2024 | -$33.9M | +50.9% |
| FY2023 | -$69.1M | +58.5% |
| FY2022 | -$166.6M | +17.7% |
| FY2021 | -$202.5M | +13.2% |
| FY2020 | -$233.3M | +6.8% |
| FY2019 | -$250.4M | +16.5% |
| FY2018 | -$300.0M | -40.4% |
| FY2017 | -$213.7M | -42.3% |
| FY2016 | -$150.1M | -49.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026